Annual Report 2016 Active Biotech AB (publ)

(Thomson Reuters ONE) -



Active Biotech's Annual Report 2016 is now available för download at
www.activebiotech.com.


The Annual Report will only be digitally distributed. The English version will
be available within short.

Lund, May 18, 2017

Tomas Leanderson
President & CEO

For further information, please contact:
Hans Kolam, CFO
Tel. +46 (0)46 192044

About Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company
with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory properties, is
in Phase 2 development for the treatment of primary progressive multiple
sclerosis and Huntington's disease. Anyara, cancer immunotherapy, previously in
clinical Phase 1-2/3 development in patients with pancreatic-, lung- or renal
cancer. Furthermore, commercial activities are conducted for the tasquinimod,
paquinimod and SILC projects. Please visit www.activebiotech.com for more
information.

Active Biotech AB
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00


This information is information that Active Biotech AB is obliged to make public
pursuant to the Securities Markets Act. The information was submitted for
publication at 14.30 am CET on May 18, 2017.


Annual Report 2016 Active Biotech AB (publ):
http://hugin.info/1002/R/2105966/799386.pdf



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via GlobeNewswire

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 18.05.2017 - 14:30 Uhr
Sprache: Deutsch
News-ID 543034
Anzahl Zeichen: 2017

contact information:
Town:

LUND

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 115 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Annual Report 2016 Active Biotech AB (publ)"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech